Melanotan-2 MT-II UK 2026 Research Reference: Non-Selective Melanocortin Agonism, Pigmentation Pharmacology and Research Protocol Design

Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption

Table of Contents

• 1. Overview — MT-II’s position in melanocortin research
• 2. Development history — University of Arizona
• 3. Molecular structure
• 4. Melanocortin receptor pharmacology
• 5. MC1R and melanogenesis — the tanning mechanism
• 6. Pharmacokinetics
• 7. Pigmentation research applications
• 8. MC4R research applications
• 9. MT-II vs PT-141 — the same scaffold, different selectivity
• 10. MT-II vs afamelanotide (Scenesse)
• 11. Safety profile and known adverse signals
• 12. Melanoma theoretical concerns — evidence review
• 13. Reconstitution, storage and stability
• 14. UK research protocol design
• 15. UK research-grade sourcing standards
• FAQ
• References

1. Overview — MT-II’s position in melanocortin research

Melanotan-2 occupies a distinctive historical position in melanocortin research: it was among the first engineered melanocortin analogues to demonstrate that a small synthetic peptide could produce a robust systemic melanogenic response — i.e. tanning without ultraviolet exposure. The research programme that produced MT-II at the University of Arizona in the 1980s established the core structure-activity relationships for melanocortin peptide drug design and directly seeded the development of PT-141 (bremelanotide) and afamelanotide (Scenesse), both of which have reached regulatory approval while MT-II itself has not.

For UK laboratory research, MT-II’s primary value is as a non-selective melanocortin pharmacology tool. The MC1R activity that disqualified MT-II from pharmaceutical development (pigmentation is an uncontrollable side effect) is exactly what makes it useful for MC1R-focused pigmentation research, melanogenic pathway studies, and melanocyte biology.

2. Development history — University of Arizona

The MT-II research programme began in the 1980s at the University of Arizona under Professor Mac Hadley and colleagues in the College of Pharmacy. The original research question was whether a synthetic α-MSH analogue could reduce skin cancer risk by inducing protective melanogenesis without UV exposure — a preventive strategy particularly relevant for high-UV-risk populations such as organ transplant recipients on chronic immunosuppression.

The programme produced two principal compounds:

• Melanotan-1 (MT-I, afamelanotide): [Nle⁴, D-Phe⁷]α-MSH — a linear analogue of α-MSH. Eventually approved by EMA (2014) and FDA (2019) as Scenesse for erythropoietic protoporphyria (EPP).
• Melanotan-2 (MT-II): Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ — a cyclic heptapeptide with greater metabolic stability and potency. Never received regulatory approval as a finished medicine but became the structural scaffold from which PT-141 was derived.

University of Arizona licensed the MT-II and MT-I patents to Competitive Technologies Inc., which sub-licensed to Palatin Technologies for further development. Palatin subsequently focused on PT-141 for sexual function, and on Setmelanotide (an MC4R-selective agonist, approved 2020 as Imcivree for rare genetic obesity conditions).

3. Molecular structure

Melanotan-2 is a cyclic heptapeptide:

Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂

Molecular formula C₅₀H₆₉N₁₅O₉; molecular weight approximately 1024 Da (different sources cite values within 1024-1025 Da depending on calculation convention).

Structural features:

• N-terminal acetyl group for metabolic stability
• Nle (norleucine) at position 1 — corresponds to α-MSH position 4 (Met → Nle substitution removes the oxidation-labile methionine)
• Cyclic lactam bridge between Asp²-Lys⁷ side chains — forms the heptapeptide loop that constrains 3D conformation and improves receptor residence
• D-Phe⁴ substitution — enhances receptor affinity and metabolic stability compared to native L-Phe
• His-Phe-Arg-Trp (HFRW) core motif — the conserved melanocortin pharmacophore shared with α-MSH, PT-141, and all melanocortin receptor agonists
• C-terminal amide — a key structural feature distinguishing MT-II from PT-141 (which has free C-terminal carboxyl)

The C-terminal amide is the key structural feature responsible for MT-II’s retained MC1R activity. Converting the amide to a free carboxyl (as in PT-141) reduces MC1R binding while preserving MC4R/MC3R binding — producing the different selectivity profile that defines the MT-II to PT-141 progression.

4. Melanocortin receptor pharmacology

Melanotan-2 is a non-selective agonist across the melanocortin receptor family. Approximate binding affinity profile (Ki in nM):

• MC1R: 0.25 nM
• MC3R: 6 nM
• MC4R: 1.5 nM
• MC5R: 0.42 nM
• MC2R: effectively no activity (no ACTH-receptor binding)

Signal transduction follows the standard class A GPCR melanocortin pathway: Gαs coupling → adenylyl cyclase → cAMP → PKA → downstream effector activation (including CREB phosphorylation and MITF transcription factor activation in melanocytes).

The non-selective profile produces a broad range of biological effects:

• MC1R activation → skin and hair pigmentation (melanogenesis)
• MC3R activation → energy homeostasis and appetite modulation
• MC4R activation → sexual behaviour, appetite, autonomic signalling
• MC5R activation → exocrine secretion modulation (sebaceous glands)

The broad pharmacological profile is simultaneously MT-II’s research utility (multiple tissue responses from a single agent) and its clinical drawback (inability to isolate a single therapeutic effect).

5. MC1R and melanogenesis — the tanning mechanism

MC1R is the key receptor in human skin pigmentation biology. It is expressed on epidermal melanocytes, and its activation triggers the melanogenic cascade:

1. MC1R activation → Gαs → cAMP → PKA → CREB phosphorylation
2. CREB-mediated transcription of MITF (microphthalmia-associated transcription factor)
3. MITF upregulates tyrosinase, TRP1, TRP2 — the rate-limiting enzymes of melanin synthesis
4. Conversion of tyrosine → DOPA → dopaquinone → eumelanin (the dark-brown pigment protective against UV)
5. Packaging of eumelanin into melanosomes, transfer to keratinocytes

MT-II activates this cascade pharmacologically, producing increased eumelanin content in skin without requiring UV trigger. The tanning effect is darkest on naturally higher-pigmented skin areas (moles, freckles, areola, perineum) because melanocyte density and baseline MITF activity are higher in those regions — a research-relevant observation for melanocyte density mapping studies.

The same pathway is responsible for the cosmetic effects that led to MT-II’s non-research use (not endorsed and outside the scope of UK research-grade laboratory supply).

6. Pharmacokinetics

• Plasma half-life: ~33 minutes
• Tmax after SC injection: 30-60 min
• Bioavailability (SC): high (>80%)
• Volume of distribution: moderate
• Protein binding: low-to-moderate
• Metabolism: peptide hydrolysis (no CYP involvement)
• Elimination: primarily renal
• Duration of biological pigmentation effect: far longer than plasma half-life — eumelanin synthesised during receptor activation persists in melanocytes and keratinocytes for weeks

The dissociation between plasma half-life (minutes) and biological effect duration (weeks for pigmentation) reflects the transcriptional/enzymatic downstream effects — once MITF has been upregulated and melanogenesis initiated, the melanin synthesis pathway runs autonomously and melanin persists until keratinocyte turnover.

7. Pigmentation research applications

UK laboratory research using MT-II in melanocortin and pigmentation biology:

• MC1R signalling studies: MT-II is the reference MC1R agonist for cAMP/PKA/CREB/MITF pathway characterisation in melanocyte cell lines (B16, SK-MEL, primary human melanocytes)
• Tyrosinase pharmacology: MT-II induces tyrosinase expression in a dose- and time-dependent manner; reference tool for enzyme induction studies
• Melanogenic gene expression: MT-II + RNA-seq or microarray analysis reveals the full MC1R-downstream transcriptional programme
• MC1R polymorphism research: comparing MT-II response in different MC1R variants (RHC variants, R151C, R160W etc.) informs the genetic basis of skin colour variation and melanoma risk
• Melanosome biology: MT-II-stimulated cells are used to study melanosome biogenesis, maturation and transfer to keratinocytes
• Photoprotection research: assessing whether MT-II-induced melanogenesis can protect keratinocytes from UV-induced DNA damage in controlled in vitro models

8. MC4R research applications

Although PT-141 is now the preferred MC4R-research tool (due to its reduced off-target MC1R activity and regulatory-approval status), MT-II retains applications in MC4R research:

• Broad melanocortin system activation in energy-balance and appetite research (rodent models)
• Male sexual behaviour research in rodent models (the erectogenic effects that motivated PT-141’s development were first observed with MT-II)
• Autonomic function research — MT-II produces more pronounced transient blood pressure effects than PT-141, useful where cardiovascular autonomic outputs are the research target

9. MT-II vs PT-141 — the same scaffold, different selectivity

MT-II and PT-141 (bremelanotide) share the cyclic heptapeptide backbone but differ in receptor selectivity owing to a single structural change.

For UK research protocol design, choose MT-II for MC1R-focused pigmentation biology; choose PT-141 for MC4R-focused sexual function, neurobiology, or obesity research.

10. MT-II vs afamelanotide (Scenesse)

Afamelanotide (the pharmaceutical name for Melanotan-1, MT-I) is the linear α-MSH analogue also developed from the University of Arizona programme. Differences:

• Structure: afamelanotide is linear (not cyclic); MT-II is cyclic
• Half-life: afamelanotide as a slow-release implant has effective tissue presence of ~60 days; MT-II is a short-acting injectable
• Approval: afamelanotide approved by EMA (2014) and FDA (2019) for erythropoietic protoporphyria (EPP) under the brand name Scenesse; MT-II not approved
• Research overlap: both are melanocortin agonists with MC1R-mediated melanogenic effects; afamelanotide is increasingly the preferred research tool where a regulated, named, clinically-studied comparator is required

For UK research protocols requiring a regulated comparator or comparison to clinical EPP pharmacology, afamelanotide (Clinuvel-supplied implant, or research-grade peptide equivalent) is preferable. For in vitro and early-preclinical MC1R pharmacology, MT-II remains the most widely-cited research tool.

11. Safety profile and known adverse signals

Known adverse events from human exposure studies and case-series data:

• Transient nausea: 30-50% at supra-physiological doses
• Flushing: frequent
• Injection site reactions
• Spontaneous erection (MC4R-driven, unintended effect): documented in male research participants, especially at higher doses
• Transient blood pressure elevation and tachycardia
• Focal hyperpigmentation — can persist for weeks to months
• Darkening of moles and pre-existing nevi (not necessarily pathological but cosmetically concerning and a confounder in any skin-lesion surveillance)
• Loss of appetite and modest weight loss (MC4R-mediated)
• Rare priapism case reports

MT-II is not an approved medicine. All commercial or quasi-commercial MT-II supply in the UK is to research establishments for laboratory use only.

12. Melanoma theoretical concerns — evidence review

A frequent theoretical concern raised about MT-II is whether chronic MC1R activation could increase melanoma risk, given that MC1R signalling is associated with melanocyte proliferation. The current evidence:

• Biological plausibility: chronic MC1R activation could in theory provide a melanocyte-proliferation signal, though the dominant protective effect is eumelanin UV-shielding
• Animal data: no unambiguous melanoma signal in rodent or primate MC1R-agonist exposure studies
• Human case reports: isolated case reports of melanoma diagnosed in MT-II users exist but causal attribution is confounded by prior UV exposure, baseline skin type, and co-morbidity
• Epidemiologic data: limited and inconclusive — no controlled prospective data
• Afamelanotide (the approved analogue, same MC1R activation profile): post-marketing surveillance since 2014 in Europe has not produced a significant melanoma signal

The balance of published evidence does not support a strong causal link between MT-II use and melanoma, but residual uncertainty remains. The appropriate research-protocol position is: exclude participants with history of melanoma or dysplastic naevus syndrome, include dermatologic baseline and periodic skin-lesion monitoring, and maintain comprehensive adverse event recording.

13. Reconstitution, storage and stability

MT-II typical research-grade vial: 10 mg lyophilised powder. Reconstitution:

• Add 2 mL bacteriostatic water (0.9% benzyl alcohol preserved) → 5 mg/mL
• Post-reconstitution storage: 2-8°C, use within 30-45 days
• Protect from light and freezing
• Lyophilised powder (unreconstituted) stable at −20°C for >2 years

MT-II aqueous stability is good owing to the cyclic structure and absence of oxidation-labile residues (Nle replaces Met). Aggregation is not a significant issue at research concentrations.

14. UK research protocol design

Typical UK laboratory research protocols using MT-II:

• In vitro melanocyte research: 1-100 nM MT-II in melanocyte culture media; time-course 24-96 hours; readouts include cAMP accumulation, MITF expression, tyrosinase activity, and melanin content
• Rodent pigmentation research: typical doses 0.1-1 mg/kg SC; skin biopsy at defined time points; readouts include histological melanin content and mRNA expression
• MC4R pharmacology in rodents: 0.1-0.5 mg/kg SC for appetite, sexual behaviour, and autonomic-function readouts
• Non-human primate melanocyte studies: dose-response with careful dermatologic monitoring
• Comparative melanocortin studies: MT-II paired with PT-141 (MC4R selectivity), afamelanotide (MC1R linear analogue), and MC4R-selective agonists (setmelanotide) to dissect receptor-specific contributions

15. UK research-grade sourcing standards

MT-II should be sourced with full documentation:

• ≥98% HPLC purity (≥99% is the emerging 2026 standard)
• Mass spectrometry identity confirmation
• Batch-specific Certificate of Analysis
• Endotoxin quantification
• Residual TFA analysis
• Cyclisation integrity confirmation (LC-MS distinguishing cyclic from linear isomers)
• C-terminal amide confirmation (critical distinction from PT-141 free carboxyl)
• Lyophilised powder with cold-chain shipping

Quality-control note: MT-II and PT-141 are near-identical in amino acid sequence. An inadequately QC’d batch of MT-II could be contaminated with PT-141 or the reverse. Mass spectrometry distinguishes the two (MT-II MW 1024 Da; PT-141 MW 1025 Da — 1 Da difference corresponding to amide→carboxyl). A high-quality COA should specifically confirm the expected MW.

FAQ

Is MT-II the same as PT-141?
No. They share the cyclic heptapeptide backbone but MT-II has C-terminal amide and high MC1R activity (causing tanning), while PT-141 has C-terminal carboxyl and reduced MC1R activity (minimal tanning). PT-141 is approved as Vyleesi; MT-II is not approved.

Is MT-II legal to supply in the UK for research?
Yes, as research-grade material for in vitro and preclinical laboratory use. MT-II is not MHRA-approved as a medicine and is not for human consumption. UK research-grade suppliers supply for controlled laboratory research use only.

Does MT-II cause melanoma?
No strong causal link established. The theoretical biological plausibility exists (MC1R-driven melanocyte proliferation) but epidemiological and clinical data do not support a significant risk increase. Research protocols exclude participants with melanoma history and include skin-lesion surveillance as a safety measure.

Why was MT-II never approved?
The non-selective receptor profile produced multiple simultaneous effects (tanning, appetite suppression, erections, blood pressure changes) that could not be isolated. The programme pivoted to subtype-selective descendants — PT-141 for MC4R, afamelanotide for MC1R — which reached approval.

Can MT-II be combined with other melanocortin peptides?
For research purposes, combinations are used to dissect receptor-specific contributions (e.g. MT-II + MC4R-selective antagonist to isolate non-MC4R effects). Combination of MT-II with PT-141 would produce redundant MC4R activation without adding dissection value.

Why is afamelanotide approved but MT-II not?
Afamelanotide’s linear structure and slow-release implant formulation gave a defined pharmacokinetic profile and a specific indication (EPP photosensitivity) where the MC1R-melanogenic mechanism provides direct therapeutic benefit. MT-II’s shorter half-life and non-selective profile never identified a sufficiently narrow therapeutic indication for regulatory approval.

What’s setmelanotide’s relationship to MT-II?
Setmelanotide (Imcivree, Rhythm Pharmaceuticals) is an MC4R-selective agonist approved in 2020 for rare monogenic obesity conditions (POMC deficiency, LEPR deficiency, Bardet-Biedl syndrome). It derives from the same melanocortin research lineage but is structurally distinct from MT-II and has much greater MC4R selectivity.

References

1. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides 2006;27:921–930.
2. Dorr RT et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dermatol 2004;140:827–835.
3. Al-Obeidi F et al. Design of a new class of superpotent cyclic alpha-melanotropins based on quenched dynamic simulations. J Am Chem Soc 1989;111:3413–3416.
4. Ugwu SO et al. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm Drug Dispos 1997;18:259–269.
5. Molinoff PB et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci 2003;994:96–102.
6. Minder EI et al. Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria. Expert Opin Investig Drugs 2010;19:1591–1602.
7. Langan EA et al. Melanotropic peptides: more than just ‘Barbie drugs’ and ‘sun-tan jabs’? Br J Dermatol 2010;163:451–455.
8. Cao C et al. Melanocortin receptors: their relation to Parkinson’s disease, hypertension and melanoma. J Integr Neurosci 2015;14:557–577.
9. Rouzaud F, Hearing VJ. Regulatory elements of the melanocortin 1 receptor. Peptides 2005;26:1858–1870.
10. Tao YX. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev 2010;31:506–543.

UK Research Cluster Hubs

• GLP-1 Research Hub
• Tirzepatide Hub
• Retatrutide Hub
• BPC-157 Research Hub
• TB-500 Research Hub
• Growth-Hormone Peptides Hub
• Research-Grade Buyer’s Guide

Disclaimer: All peptides referenced are sold strictly for in vitro laboratory research use. Not for human consumption, veterinary use, food additive, cosmetic, or household purpose. Nothing in this article is medical advice. UK researchers are responsible for compliance with the Human Medicines Regulations 2012 and Misuse of Drugs Regulations 2001 where applicable.